A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 17, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Healthy

Interventions

DRUG

IMP761

intravenous

DRUG

Placebo

intravenous

OTHER

keyhole limpet haemocyanin (KLH)

intramuscular immunization and intradermal challenge

Trial Locations (1)

RECRUITING

CHDR, Leiden

All Listed Sponsors

lead

Immutep S.A.S.

INDUSTRY